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Background: The aetiology of idiopathic pulmonary fibrosis remains poorly understood, but
recent studies have suggested that diabetes mellitus and gastro-oesophageal reflux may be risk
factors.
Objective: To test possible associations between diabetes mellitus and gastro-oesophageal re-
flux with idiopathic pulmonary fibrosis in the general population.
Methods: We designed a caseecontrol study in the setting of UK general practices contributing
data to The Health Improvement Network primary care database (THIN). We selected patients
over 40 years of age with a first diagnosis of idiopathic pulmonary fibrosis, and up to 4 controls
per case matched by age, gender, and general practice. We estimated odds ratios for exposure
to gastro-oesophageal reflux, gout, hypercholesterolaemia and diabetes mellitus using condi-
tional logistic regression. We explored the role of confounding by smoking habit, socio-
economic status, and medication with prednisolone.
Results: Amongst our 920 cases we found increased risks of use of insulin (odds ratio (OR) 2.36;
95% confidence interval (CI) 1.46e3.83) and use of ulcer drugs (OR 2.20; 95% CI 1.88e2.58).
These were almost unchanged when we excluded cases and controls who had been prescribed
prednisolone. We found no association with hypercholesterolaemia or gout, nor with smoking
status or socio-economic status.
Conclusions: The study provides further evidence of an association between idiopathic pulmo-
nary fibrosis and both diabetes mellitus and gastro-oesophageal reflux.
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Table 1 Description of cases and controls.
Cases % Controls %
nZ 920 3593
Age
Mean age 71.4 71.4
Age group
<55 years 79 9 311 9
55e64.9 years 166 18 646 18
65e74.9 years 290 32 1134 32
75e84.9 years 302 33 1176 33
>85 years 83 9 326 9
Gender
Females 352 38 1365 38
Males 568 62 2228 62
Smoking habit
Non-smoker 355 39 1420 40
Current smoker 240 26 877 24
Ex-smoker 192 21 714 20
Status not available 133 14 582 16
Socio-economic status (Townsend quintile)
1 (least deprived) 174 19 718 20
2 169 18 665 19
3 189 21 667 19
4 158 17 670 19
5 (most deprived) 130 14 487 14
0 (unavailable) 100 11 386 11
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Idiopathic pulmonary fibrosis (IPF) is recognised increas-
ingly as an important cause of morbidity1 and premature
mortality2 in the UK and USA. Recent estimates suggest
4000 new cases of IPF occur each year in the UK3 and 18,000
in the USA.4 There is evidence that the incidence of IPF is
increasing,3 but its aetiology remains poorly understood.
Recently, two potential risk factors for IPF have been
proposed. In a study of 52 Japanese cases, Enomoto et al5
found a higher prevalence of diabetes mellitus compared to
their controls, but a study by Miyake et al of 104 cases
found no association with diabetes.6 The caseecontrol
study of Raghu et al7 found a higher prevalence of abnormal
acid gastro-oesophageal reflux in their 17 cases. To inves-
tigate these new ideas further we have performed a casee
control study using prospectively collected data from
general practices in the UK to determine the role of dia-
betes mellitus and gastro-oesophageal reflux for IPF.
Methods
The Health Improvement Network (THIN) is a longitudinal
primary care database which includes diagnostic and
prescribing data recorded by UK general practitioners as
part of routine clinical care. It has been shown to have
a high level of completeness of clinical, diagnostic and
prescribing data.8,9
Details of case identification of cases and controls have
been published previously3 but, briefly, we selected IPF
cases from the period 1991e2003 who were over 40 years of
age when they received their first diagnosis for IPF, and up
to 4 contemporaneous controls per case matched by age,
gender, and general practice. The Read Code (diagnostic
terms) that we used to construct our look-up table to
identify cases were ‘‘cryptogenic fibrosing alveolitis’’ and
‘‘idiopathic fibrosing alveolitis’’ which reflect the clinical
terms commonly used in the UK over the last 20 years.
Our main exposures of interest were diabetes mellitus
and gastro-oesophageal reflux. We also looked for associa-
tions with hypercholesterolaemia and gout, for which no
associations between these conditions and IPF have been
proposed. The rationale for this was that an association
between IPF and chronic diseases in general could point
towards ascertainment bias in the diagnosis of IPF for
patients treated for chronic disease.
To examine these we extracted data on clinical diag-
noses or relevant prescriptions (insulin, oral hypo-
glycaemics, antacids, ulcer drugs, allopurinol, lipid drugs)
before the first diagnosis of IPF (for cases) or matching date
(controls).
Our potential confounders were cigarette smoking,
socio-economic status and use of prednisolone. We coded
smoking habit as ex-, current-, or non-smoker. Our marker
of socio-economic status was Townsend score, which is an
index derived from 2001 census data comprising prevalence
of household access to a car, owner occupation, over-
crowding, and unemployment within the patient’s
postcode.
We used conditional logistic regression in Stata version 9
to estimate odds ratios for each exposure, matching by age,gender and practice. Initially we estimated odds ratios for
each of our exposures and confounders in a series of
univariate models. Variables were selected for multivariate
analysis by identifying the variable within each group of
related diagnoses and prescriptions which had the largest
odds ratio with a p value of not more than 0.1.
We explored the influence of confounders in a series of
bivariate models, in which we looked for a change in the
odds ratio for exposure of 10% or more with the addition to
the model of the putative confounder. We undertook
further multivariate analysis to check for independent
effects between each of the variables corresponding to
diagnoses and prescriptions for diabetes and gastro-oeso-
phageal reflux.
Prednisolone is known to cause diabetes mellitus and
gastro-oesophageal reflux, and is often prescribed to
people with respiratory symptoms. Therefore to provide
further reassurance that there was no confounding by
prednisolone, we carried out a restricted analysis excluding
all cases and controls with any exposure to prednisolone.
The study protocol was reviewed and approved by the
Nottingham Research Ethics Committee.
Results
We identified 920 people with IPF who were over the age of
40 years when they received their first diagnosis,3 and 3593
matched controls. The mean age of people with IPF at
presentation was 71 years (standard deviation 11 years) and
568 (62%) were male. The age distribution of cases is shown
in Table 1. About a quarter of cases were current smokers,
with a further fifth recorded as ex-smokers. In 14% of the
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no clear association between case status and Townsend
score.
We recorded the results of our univariate analyses in
Table 2. Odds ratios obtained for gout and allopurinol, and
for hypercholesterolaemia, lipid drugs and statins were
close to 1 and were not significant at the 5% level. Similarly,
we found no significant associations for smoking or socio-
economic status.Table 2 Results of univariate analyses.
Cases (nZ 920) Controls (nZ 35
Diagnosis of diabetes
mellitus
89 (10%) 275 (8%)
Oral hypoglycaemic
agents
64 (7%) 184 (5%)
Insulin 29 (3%) 45 (1%)
Diagnosis of gout 39 (4%) 154 (4%)
Allopurinol 20 (2%) 92 (3%)
Diagnosis of
gastro-oesophageal
reflux
108 (12%) 279 (8%)
Antacids 272 (30%) 727 (20%)
Ulcer drugs 375 (41%) 889 (25%)
Diagnosis of
hypercholesterolaemia
56 (6%) 220 (6%)
All lipid drugs 90 (10%) 326 (9%)
Statins only 78 (8%) 281 (8%)
Prednisolone 334 (36%) 367 (10%)
Smoking habit
Non-smoker 355 (39%) 1420 (40%)
Current smoker 240 (26%) 877 (24%)
Ex-smoker 192 (21%) 714 (20%)
Status not available 133 (14%) 582 (16%)
Not ever smoked 355 (39%) 1420 (40%)
Ever smoked 432 (47%) 1591 (44%)
Status not available 133 (14%) 582 (16%)
Smoking amount
(cigarettes/day)
Non-smoker, 0 cigs
per day
488 (53%) 2002 (56%)
1e9 cigs per day 44 (5%) 144 (4%)
10e19 cigs per day 47 (5%) 171 (5%)
20þ cigs per day 44 (5%) 180 (5%)
Current smoker,
0 cigs per day
105 (11%) 382 (11%)
Ex-smoker,
0 cigs per day
192 (21%) 714 (20%)
Socio-economic status (Townsend quintile)
1 (least deprived) 174 (19%) 718 (20%)
2 169 (18%) 665 (19%)
3 189 (21%) 667 (19%)
4 158 (17%) 670 (19%)
5 (most deprived) 130 (14%) 487 (14%)
0 (unavailable) 100 (11%) 386 (11%)Odds ratios for gastro-oesophageal reflux and associ-
ated medication were all raised: diagnosis of gastro-
oesophageal reflux 1.65 (95% confidence interval (CI)
1.29e2.10), antacids 1.71 (95% CI 1.44e2.02), ulcer drugs
2.22 (95% CI 1.89e2.60). We also found positive associa-
tions for diabetes mellitus 1.31 (95% CI 1.01e1.70), oral
hypoglycaemic agents 1.40 (95% CI 1.04e1.88), insulin 2.56
(95% CI 1.60e4.11), and prescribing for prednisolone 5.61
(95% CI 4.64e6.77).93) Odds ratio (95% confidence interval)
1.31 (1.01e1.70) pZ 0.038
1.40 (1.04e1.88) pZ 0.027
2.56 (1.60e4.11) p < 0.001
0.99 (0.68e1.44) pZ 0.943
0.84 (0.52e1.38) pZ 0.493
1.65 (1.29e2.10) p < 0.001
1.71 (1.44e2.02) p < 0.001
2.22 (1.89e2.60) p < 0.001
1.00 (0.73e1.37) pZ 0.994
1.11 (0.85e1.45) pZ 0.432
1.12 (0.84e1.48) pZ 0.441
5.61 (4.64e6.77) p < 0.001
1.00
1.12 (0.92e1.36)
1.10 (0.89e1.35)
0.90 (0.71e1.14) pZ 0.324
1.00
1.11 (0.93e1.31)
0.90 (0.71e1.14) pZ 0.178
1.00
1.29 (0.90e1.83)
1.15 (0.81e1.62)
1.03 (0.72e1.47)
1.15 (0.89e1.48)
1.13 (0.93e1.38) pZ 0.613
1.00
1.05 (0.82e1.34)
1.18 (0.92e1.51)
0.99 (0.75e1.27)
1.11 (0.84e1.48)
1.11 (0.66e1.88) pZ 0.686
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in the multivariate analysis. Our multivariate model gave
an odds ratios of 2.36 (95% CI 1.46e3.83, p < 0.001) for
insulin and 2.20 (95% CI 1.88e2.58, p < 0.001) for ulcer
drugs. We also undertook further multivariate analysis for
diabetes and gastro-oesophageal reflux to check for inde-
pendent effects between each of the variables corre-
sponding to diagnoses and prescriptions; this did not
produce any marked differences compared to the results
shown in Table 3.
Table 3 also records the restricted multivariate analysis
excluding cases and controls medicated with prednisolone.
This gave an almost unchanged odds ratio of 2.40 for insulin
(95% CI 1.26e4.58), and a slightly reduced odds ratio of
1.71 for ulcer drugs (95% CI 1.38e2.11).
Discussion
Findings
In this large caseecontrol study of prospectively collected
exposure data, we found that IPF is significantly associated
with exposures relating to diabetes, the strongest associa-
tion being with use of insulin. Our results were similar when
we excluded people with prescriptions for prednisolone.
We also found IPF to be significantly associated with
exposures relating to gastro-oesophageal reflux, amongst
which the strongest association was with prescribing for
ulcer drugs. The odds ratio for this association was reduced
from 2.20 to 1.71 by removing all people with any exposure
to prednisolone, which suggests that the use of predniso-
lone partly explains this association. We found no signifi-
cant associations between IPF and hypercholesterolaemia,
gout, smoking or socio-economic status.
Strengths and weaknesses
The main strength of our study is the large number of cases,
and that our data were collected prospectively which
means that recall is not a source of bias. The main potential
weaknesses of our study are the validity of the diagnoses of
IPF and of exposures, and possible ascertainment bias.
THIN has been developed by the designer and former
owner of the General Practice Research Database (GPRD).Table 3 Results of multivariate analyses.
Cases Controls Odds
ratio
(95%
confidence
interval)
n 920 3593
Insulin 29 45 2.36 (1.46e3.83) p < 0.001
Ulcer
drugs
375 889 2.20 (1.88e2.58) p < 0.001
Excluding cases prescribed prednisolone
n 586 3226
Insulin 16 43 2.40 (1.26e4.58) pZ 0.008
Ulcer
drugs
191 726 1.71 (1.38e2.11) p < 0.001More than half of THIN practices previously contributed data
to GPRD which has demonstrated high validity for diagnoses
and coding of respiratory diseases.10 The validity of the
diagnoses is consistent with the expectation that general
practitioners will record a diagnosis of IPF only when it is
confirmed by a hospital referral, and will have coded it using
‘‘cryptogenic fibrosing alveolitis’’ and ‘‘idiopathic fibrosing
alveolitis’’, which are the only relevant Read codes available
to them in their computer system for recording such a diag-
nosis. Further reassurance about the validity of our disease
diagnoses is given by the fact that the demographic profile
andmortality of our cases appear similar to that reported for
other cohorts.1,11e13 The validity of the medication expo-
sures derives from the fact that the records are integral to
the generation of prescriptions in general practices.
The possibility of bias due to differential ascertainment
arises because people with diagnosed diabetes or gastro-
oesophageal reflux may have received a different level of
medical attention than those without. We cannot exclude
this as a source of bias, but the fact that associations
between either reflux or diabetes and IPF are not widely
recognised amongst general practitioners in the UK,
together with the fact that we found no associations for
gout and hypercholesterolaemia argues against this being
an important bias in our dataset.Other studies
An association between gastro-oesophageal reflux and
diffuse pulmonary fibrosis has been suspected for more than
30 years.14 One study found that 16 out of 17 patients with
IPF had evidence of reflux compared to 4 out of 8 patients
with other interstitial lung diseases.15 A more recent study
found that gastro-oesophageal reflux is highly prevalent in
IPF but often clinically occult.7 To date, however, there has
been no systematic epidemiological investigation of the link
between gastro-oesophageal reflux and IPF.
The strength of the association which we found with
gastro-oesophageal reflux was weaker than earlier studies.
Amongst our 920 cases only 12% had a diagnosis of gastro-
oesophageal reflux compared to 47% of the 55 cases in
a smaller recent study,7 and compared to 25% of the 17
cases in a pilot study.15 Possible reasons for this (aside from
variation arising from the relatively small sample sizes of
earlier studies) include variations in criteria used for gas-
tro-oesophageal reflux. Raghu et al counted all patients
who on questioning reported the presence of ‘‘classic
symptoms’’ whereas we counted pre-existing diagnoses.
There may also be differences in the denominator arising
from differing case definitions, which would give rise to
a dilution of the estimate of the odds ratio. For example,
Raghu et al use criteria based on the international
consensus statement16 which may be more specific than our
criteria. In the UK, only a small minority of patients have an
open lung biopsy,17 so our definition includes adults who
have a diagnosis made on clinical grounds, and recorded
using the terms ‘‘cryptogenic fibrosing alveolitis’’ and
‘‘idiopathic fibrosing alveolitis’’, which reflect the clinical
terms commonly used in the UK over the last 20 years.
This variation in case definition may also be a contribu-
tory factor in explaining the much lower prevalence of
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study of Enomoto et al.5 Their study of 52 patients and 184
controls in Japan found a prevalence of 33%, whereas our
study found a recorded diagnosis of diabetes in 10% of our
920 cases (or, on a like for like basis with Enomoto et al, 9%
amongst our 586 cases who had not received prednisolone
prior to diagnosis). However, the adjusted odds ratio found
in Enomoto’s smaller study (odds ratio 4.06) falls within the
95% confidence intervals of our estimate (1.26e4.58) which
is based on a larger sample. Miyake et al found a prevalence
of 12.5% amongst their 104 cases.6 Their adjusted odds
ratio of 1.43 also falls within the confidence intervals of our
estimate.
What does it mean clinically?
The association between IPF and a diagnosis of gastro-
oesophageal reflux, or its management with medication,
is consistent with the hypothesis that gastro-oesophageal
reflux is an important risk factor for IPF. The temporality
of pre-existing gastro-oesophageal reflux in this associa-
tion is consistent with a causal link with gastro-oeso-
phageal reflux or its management in some cases.
Intervention trials are needed to determine whether
treatments for reflux can slow disease progression in
people with IPF.
Similarly, the associations with pre-existing diagnosis
and management of diabetes mellitus are consistent with
a relationship in which diabetes is a causal factor for IPF.
Our finding of a stronger association with insulin than with
oral hypoglycaemics is consistent with a relationship in
which Type 1 and Type 2 diabetes represent exposures
that are distinct in terms of their influence on the
development of IPF, or one in which the early onset of the
exposure is important. This suggests that clinicians should
be alert to the possibility of diabetes mellitus in people
diagnosed with IPF.
Conclusion
Our study provides further evidence that there is
a temporal association between diabetes mellitus and IPF,
and between gastro-oesophageal reflux and IPF. We did not
find evidence to support a link with smoking or socio-
economic status.
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